lundi 20 janvier 2020

Onco Actu du 20 janvier 2020


1. BIOLOGIE



Heterogeneity of Liver Cancer Cells Helps Explain Tumor Progression in Patients, Mount Sinai Research Found [Mount Sinai]











1.1 BIOLOGIE - GÉNOME



Frequency, Mutational Patterns, and Genomic Profile of Hypermutated Breast Cancer [ESMO]











2.5 ETIOLOGIE - GÉNOME



Loss of Function in Key Y-Chromosome Genes Increases Cancer Risk in Men [Barcelona Institute for Global Health]











Y chromosome may expose men to greater cancer risk, study finds [UPI]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Incidental Imaging Findings in Clinical Trials [JAMA]











4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



“Potential to eliminate” cervical cancer in England thanks to NHS Long Term Plan [NHS England]










Cervical cancer could be eliminated in England, experts say [The Guardian]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Cheap drug may alleviate treatment-resistance in leukemia [Karolinska Institutet]











5.10 TRAITEMENTS - ESSAIS



Despite U.S. law, many clinical trial results go unreported [Reuters]










5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Deciphering a cancer treatment’s dark side [Science]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Tweaking how CAR-T therapy kills tumors could stop a dangerous side effect, study finds [STAT]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer [AstraZeneca]











5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



Bracing for a hematology faceoff: CARs vs. bispecifics [ORF]











5.2 PHARMA



Lynparza regulatory submission granted Priority Review in the US for HRR-mutated metastatic castration-resistant prostate cancer [AstraZeneca]











5.2.6 PHARMA - BIOTECH



Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers [Xconomy]











5.3 TRAITEMENTS - FDA, EMA,...



EMA suspends Picato as a precaution while review of skin cancer risk continues [EMA]










5.4.1 TRAITEMENTS - ECONOMIE - NICE



NICE encourages further data collection on ‘game changing’ histology independent cancer drugs [NICE]











New breed of targeted cancer drug gets initial ‘no’ for NHS in England [Cancer Research UK]











5.4.2 TRAITEMENTS - ECONOMIE - IQWIG



Germany’s IQWiG finds first tumor-agnostic drug provides no added benefit [EndPoints]











6.1 OBSERVATION



Adolescent and Young Adult Cancer Survivors May Have an Elevated Risk of Hospitalizations [AACR]










6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES



China is closing gap with United States on research spending [Nature]